Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 01 06 2022
accepted: 09 09 2022
revised: 08 09 2022
pubmed: 17 10 2022
medline: 2 2 2023
entrez: 16 10 2022
Statut: ppublish

Résumé

Peripapillary hyperreflective ovoid mass-like structures (PHOMS) have recently been described as new optical coherence tomography (OCT) marker. It is not yet clear whether the occurrence of PHOMS is disease-specific or disease-spanning. PHOMS have been described in 16-18% of patients with multiple sclerosis (MS). Currently, no data on the prevalence of PHOMS in other demyelinating diseases including aquaporine-4-IgG-positive neuromyelitis optica spectrum disease (AQP4 + NMOSD) or myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) are reported. We performed a cross-sectional, retrospective spectral domain OCT study evaluating the frequency of PHOMS in AQP4 + NMOSD (n = 47) and MOGAD (n = 44) patients. To test the association with retinal neuroaxonal damage, we compared demographic and clinical data as well as retinal layer thicknesses between eyes with vs. eyes without PHOMS. PHOMS were detected in 17% of AQP4 + NMOSD and 14% of MOGAD patients. Intra-cohort analysis revealed that AQP4 + NMOSD patients with PHOMS were significantly older [mean (years): 57.5 vs. 50.0; p value = 0.04]. We found no association of PHOMS with retinal neuroaxonal degeneration. In addition, in subjects with only one eye affected by PHOMS compared with the unaffected fellow eye, no differences in retinal parameters were observed (n = 4). In summary, we found PHOMS in 17% of AQP4 + NMOSD and 14% of MOGAD patients. This is comparable to the prevalence of published MS PHOMS data. Therefore, a disease-specific occurrence of PHOMS is unlikely. Interestingly, PHOMS do not seem to depend on retinal neuroaxonal degeneration.

Sections du résumé

BACKGROUND BACKGROUND
Peripapillary hyperreflective ovoid mass-like structures (PHOMS) have recently been described as new optical coherence tomography (OCT) marker. It is not yet clear whether the occurrence of PHOMS is disease-specific or disease-spanning. PHOMS have been described in 16-18% of patients with multiple sclerosis (MS). Currently, no data on the prevalence of PHOMS in other demyelinating diseases including aquaporine-4-IgG-positive neuromyelitis optica spectrum disease (AQP4 + NMOSD) or myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) are reported.
METHODS METHODS
We performed a cross-sectional, retrospective spectral domain OCT study evaluating the frequency of PHOMS in AQP4 + NMOSD (n = 47) and MOGAD (n = 44) patients. To test the association with retinal neuroaxonal damage, we compared demographic and clinical data as well as retinal layer thicknesses between eyes with vs. eyes without PHOMS.
RESULTS RESULTS
PHOMS were detected in 17% of AQP4 + NMOSD and 14% of MOGAD patients. Intra-cohort analysis revealed that AQP4 + NMOSD patients with PHOMS were significantly older [mean (years): 57.5 vs. 50.0; p value = 0.04]. We found no association of PHOMS with retinal neuroaxonal degeneration. In addition, in subjects with only one eye affected by PHOMS compared with the unaffected fellow eye, no differences in retinal parameters were observed (n = 4).
CONCLUSIONS CONCLUSIONS
In summary, we found PHOMS in 17% of AQP4 + NMOSD and 14% of MOGAD patients. This is comparable to the prevalence of published MS PHOMS data. Therefore, a disease-specific occurrence of PHOMS is unlikely. Interestingly, PHOMS do not seem to depend on retinal neuroaxonal degeneration.

Identifiants

pubmed: 36245037
doi: 10.1007/s00415-022-11381-8
pii: 10.1007/s00415-022-11381-8
pmc: PMC9886610
doi:

Substances chimiques

Aquaporin 4 0
Myelin-Oligodendrocyte Glycoprotein 0
Immunoglobulin G 0
Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1135-1140

Informations de copyright

© 2022. The Author(s).

Références

Fraser JA, Sibony PA, Petzold A, Thaung C, Hamann S, ODDS Consortium (2021) Peripapillary hyper-reflective ovoid mass-like structure (PHOMS): an optical coherence tomography marker of axoplasmic stasis in the optic nerve head. J Neuroophthalmol 41(4):431–441. https://doi.org/10.1097/WNO.0000000000001203
doi: 10.1097/WNO.0000000000001203
Petzold A, Coric D, Balk LJ et al (2020) Longitudinal development of peripapillary hyper-reflective ovoid masslike structures suggests a novel pathological pathway in multiple sclerosis. Ann Neurol 88(2):309–319. https://doi.org/10.1002/ana.25782
doi: 10.1002/ana.25782
Wicklein R, Wauschkuhn J, Giglhuber K et al (2021) Association of peripapillary hyper-reflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. Eur J Neurol. https://doi.org/10.1111/ene.15056
doi: 10.1111/ene.15056
Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729
doi: 10.1212/WNL.0000000000001729
Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 15(1):134. https://doi.org/10.1186/s12974-018-1144-2
doi: 10.1186/s12974-018-1144-2
Aly L, Havla J, Lepennetier G et al (2020) Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis. Eur J Neurol 27(11):2217–2224. https://doi.org/10.1111/ene.14416
doi: 10.1111/ene.14416
Petzold A, Biousse V, Bursztyn L et al (2020) Multirater validation of peripapillary hyperreflective ovoid mass-like structures (PHOMS). Neuroophthalmology. 44(6):413–414. https://doi.org/10.1080/01658107.2020.1760891
doi: 10.1080/01658107.2020.1760891
Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20(1):37–46
doi: 10.1177/001316446002000104
Oertel FC, Havla J, Roca-Fernández A et al (2018) Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 89(12):1259–1265. https://doi.org/10.1136/jnnp-2018-318382
doi: 10.1136/jnnp-2018-318382
Oertel FC, Outteryck O, Knier B et al (2019) Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflamm 16(1):154. https://doi.org/10.1186/s12974-019-1521-5
doi: 10.1186/s12974-019-1521-5
Havla J, Kümpfel T, Schinner R et al (2017) Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 264(1):139–151. https://doi.org/10.1007/s00415-016-8333-7
doi: 10.1007/s00415-016-8333-7
Mestre H, Mori Y, Nedergaard M (2020) The brain’s glymphatic system: current controversies. Trends Neurosci 43(7):458–466. https://doi.org/10.1016/j.tins.2020.04.003
doi: 10.1016/j.tins.2020.04.003
Carotenuto A, Cacciaguerra L, Pagani E, Preziosa P, Filippi M, Rocca MA (2021) Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability [published online ahead of print, 2021 Dec 17]. Brain. https://doi.org/10.1093/brain/awab454
doi: 10.1093/brain/awab454
Petzold A (2016) Retinal glymphatic system: an explanation for transient retinal layer volume changes? Brain 139(11):2816–2819. https://doi.org/10.1093/brain/aww239
doi: 10.1093/brain/aww239
Hamann S, Malmqvist L, Wegener M et al (2020) Young adults with anterior ischemic optic neuropathy: a multicenter optic disc Drusen study. Am J Ophthalmol 217:174–181. https://doi.org/10.1016/j.ajo.2020.03.052
doi: 10.1016/j.ajo.2020.03.052

Auteurs

Jonathan A Gernert (JA)

Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University Munich, Munich, Germany.

Rebecca Wicklein (R)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Data Integration for Future Medicine (DIFUTURE) Consortium, Munich, Germany.

Bernhard Hemmer (B)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Data Integration for Future Medicine (DIFUTURE) Consortium, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University Munich, Munich, Germany.
Data Integration for Future Medicine (DIFUTURE) Consortium, Munich, Germany.

Benjamin Knier (B)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Data Integration for Future Medicine (DIFUTURE) Consortium, Munich, Germany.

Joachim Havla (J)

Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University Munich, Munich, Germany. joachim.havla@med.uni-muenchen.de.
Data Integration for Future Medicine (DIFUTURE) Consortium, Munich, Germany. joachim.havla@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH